logo
CAPR_Science
Dr. Marbán continued, “Turning to our exosomes program, earlier this quarter, we presented results from our most advanced application of our proprietary StealthX™ platform for the production of a multivalent exosome-based vaccine or booster for COVID-19. Based on this unique platform, we were able to rapidly develop a protein-based vaccine that elicited a potent immune response without the need for an adjuvant or lipid nanoparticle carrier

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2022 and provided a corporate update

By Capricor Therapeutics
Published - Nov 10, 2022, 04:05 PM ET
Last Updated - Mar 22, 2024, 02:04 PM EDT

-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-

-Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients at World Muscle Society 2022-

-Presented New Advances in Engineered Exosome Platform at Exosome-Based Therapeutic Development Summit-

-To Host Conference Call and Webcast Today at 4:30 p.m. ET-

Article Source
Quick Links
Categories
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024